Clinical Trials Directory

Trials / Unknown

UnknownNCT06006611

Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study

Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect

Status
Unknown
Phase
Study type
Observational
Enrollment
4,201 (estimated)
Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.

Detailed description

4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.

Conditions

Interventions

TypeNameDescription
DRUGAzvudineReceived antiviral treatment with azvudine

Timeline

Start date
2023-08-05
Primary completion
2023-10-25
Completion
2023-10-30
First posted
2023-08-23
Last updated
2023-09-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06006611. Inclusion in this directory is not an endorsement.